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the Measles Control Campaign on the potential 
for measles transmission in Australia 
C. R. MacIntyre, (I) N. J. Gay,c2) H. F. Gidding, (I) B. I? Hull,(l) G. L. Gilbert,(1,3) and I? B. McIntyre(l) 
Background: The aims of this study were to determine the impact of the Australian Measles Control Campaign 
(MCC) on the transmission dynamics of measles by calculating the reproductive number (R) before and after the 
MCC, and to predict measles control in Australia in the future. 
Methods: A national serosurvey was conducted before and after the MCC. Sera were tested for anti-measles IgG 
using enzyme immunoassay (EIA). A mathematical model, using serosurvey results and vaccine coverage estimates, 
was used to calculate the change in R after the MCC. 
Results: The values of R calculated before and after the MCC were 0.90 and 0.57. At vaccine coverage levels indicated 
by the Australian Childhood Immunisation Register (ACIR), the value of R will exceed 1 (the epidemic threshold) 
in 2007-2008 nationally, and sooner in some regions of Australia. Coverage of at least 84% with two doses of MMR 
is required to sustain measles control. 
Conclusions: The Australian MCC had a significant impact on the transmission dynamics of measles. However, 
current vaccine coverage levels may result in indigenous measles transmission by 2007. Sustained efforts are required 
to improve coverage with two doses of MMR and to ensure elimination of indigenous measles transmission. 
Int J Infect Dis 2002; 6: 277-282 
INTRODUCTION 
Australia conducted a national Measles Control Cam- 
paign (MCC) in the second half of 1998. The $30 million 
campaign was designed and funded by the Department 
of Health and Family Services of the Commonwealth 
of Australia (now the Department of Health and Aging), 
and was a joint initiative with the States and Territories. 
It aimed to increase measles vaccination coverage. The 
MCC was the first stage in a longer-term strategy to 
eliminate measles from Australia and help achieve the 
World Health Organization’s goal of world-wide 
eradication between 2005 and 2010. Globally, measles is 
among the leading causes of death, and is responsible for 
more deaths than road traffic accidents or lung 
cancer.’ 
The MCC was conducted when the age for the 
second dose of measles-mumps-rubella (MMR) vaccine 
was lowered from 10-16 years to 4-5 years (prior to 
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school entry), and was accompanied by a major media 
program. The MCC had three components: (1) all 
primary school-aged children were offered MMR 
vaccine regardless of their existing immunization status; 
(2) reminder letters were sent to parents of children 
aged 12-42 months whose first dose of MMR vaccine 
(scheduled at the age of 12 months) was due or overdue, 
according to the Australian Childhood Immunisation 
Register (ACIR); and (3) an information pack was 
sent to secondary school students and their parents to 
encourage students to obtain a second dose of MMR. 
It was found that over 95% of 1.78 million school 
children aged 5-12 years were vaccinated during the 
MCC.2,3 More than 1.33 million of these children were 
vaccinated in the school program, which reached 8783 
schools throughout Australia.2 
Transmission of any disease depends on the in- 
fectivity of the agent, the duration of infectivity, rates 
of contact, and the susceptibility of contacts.4 The com- 
bined effect of these factors is summarized by R, the 
effective reproductive number, which is the average 
number of secondary cases produced by a typical case 
in a given population. When R is greater than 1, cases 
increase from one generation to the next, and an 
epidemic ensues. When R is less than 1, cases decrease 
from one generation to the next. Thus the epidemic 
threshold is defined as R=l. For acute diseases that 
confer immunity such as measles, R oscillates around 1 
in an epidemic cycle, where an epidemic begins when R 
is greater than 1. After the onset of the epidemic, R 
278 International Journal of Infectious Diseases I Volume 6, Number 4,2002 
declines as the pool of susceptible individuals is reduced. 
When R is reduced to less than 1, the number of cases 
declines, and the epidemic ends. Indigenous transmis- 
sion (endemicity) will be eliminated if R is maintained 
below the epidemic threshold (i.e. R less than l).s Thus, 
measurement of R gives an indication of measles con- 
trol. 
The aims of this study were to determine the impact 
of the MCC on the transmission dynamics of measles by 
calculating R before and after the MCC, and to predict 
measles control in Australia in the future. 
METHODS 
Serosurvey 
The serosurvey methods have been described in detail 
previously.6 Briefly, approximately 3000 sera, that would 
otherwise have been discarded, were obtained from 
diagnostic laboratories throughout Australia before 
and after the MCC, from children aged l-18 years. In 
addition, a further 2025 sera collected before the MCC 
from subjects aged 1949 years were tested for measles 
IgG antibody. Since older age groups were not targeted 
in the campaign, it was assumed that there would be no 
significant change in seroprevalence in this group. 
Within each l-year age group, States and Territories 
were sampled proportionally to their population size. 
Sample sizes were calculated to achieve confidence 
intervals of approximately ~5% for each age group, 
based on the expected level of immunity to measles. 
Approximately equal numbers of sera from males and 
females were tested. 
Sera were tested and results interpreted according 
to the manufacturer’s instructions using the Enzygnost 
(Behring Diagnostics, Marburg, Germany) anti-measles 
IgG enzyme immunoassay (EIA), at the Institute of 
Clinical Pathology and Medical Research, Sydney, 
Australia. Results were classified as positive, negative, or 
equivocal. A sensitivity analysis was done, in which data 
were analyzed initially with the equivocal results grouped 
with the positive results and then with the negative 
results. The rationale for this is that equivocal results 
usually indicate low, but not necessarily protective, levels 
of vaccine-induced antibodies.6,7 
When calculating susceptibility to measles, results 
were age standardized to adjust for disproportionate 
sampling from different age groups. As the serosurvey 
was only conducted on people aged 1 year or over, and 
knowing that maternal antibodies to measles persist in 
the first 6 months of life, we assumed 50% susceptibility 
in children aged less than 1 year. The highest age of 
people tested was 49 years. The susceptibility to measles 
in people aged over 49 years was assumed to be the 
same as that for people aged 4.5-49 years, as older adults 
have been almost universally exposed to natural in- 
fection. Serosurvey results were used to model both pre- 
and post-campaign values of R. 
Vaccine coverage estimates 
Vaccine coverage estimates were obtained using the 
ACIR.8 The ACIR is a national register which records 
the immunization status of all children aged O-7 years 
for scheduled vaccines. Australia has universal health 
insurance coverage known as ‘Medicare’. When a child 
is enrolled in Medicare after birth, they are automatically 
included in the ACIR. General practitioners (GPs) 
receive incentive payments for immunizing children and 
for notifying immunisations to the ACIR, and parents 
receive a Child Immunisation History Statement when 
the child is 12 months old, which outlines all the immu- 
nizations that the child has received. Parental incentives 
are also in place, with a maternity immunization 
allowance and childcare benefits being linked to 
immunization. The ACIR was first established in 1996, so 
that coverage data at 4 years of age are available only 
for the first birth cohort of children born in 1996. These 
data were used to estimate susceptibility to measles and 
to estimate future population trends in R. To predict 
measles control in the future, we used the ACIR MMR 
coverage data at 12 months and 4 years as a ‘worst case 
scenario’ (assuming that ACIR data represent the 
minimum possible coverage). We selected levels of 
coverage with two doses of MMR that are required to 
provide adequate herd immunity (94%) as our ‘best 
case scenario’. We selected a level of vaccine coverage 
midway between the best and worst case scenarios as a 
third, intermediate scenario. 
Postcode data were used to examine coverage by 
Divisions of General Practice (DGPs), which are geo- 
graphically defined administrative areas. There are 123 
DGPs in Australia, and 90% of GPs belong to a DGI? 
We modeled changes in R for selected DGPs with high 
and low MMR coverage around Australia. 
Modeling 
The population was stratified into five age groups: 
O-4, 5-9, 10-14, 15-19, and 20+ years. The proportion 
susceptible in each age group xi before and after the 
MCC was estimated from the seroprevalence data. Pro- 
jections of the proportion susceptible in subsequent 
years were based on the post-MCC susceptibility in each 
cohort, on the assumption that no immunity would be 
acquired through natural infection. In new cohorts, the 
proportion susceptible was estimated from the expected 
vaccine coverage and vaccine efficacy (assumed to be 
90% after one dose, and 99% after two doses). 
The potential for measles transmission was sum- 
marized by the effective reproduction number, R, the 
average number of secondary cases produced by a 
typical infective agent.9 R depends on the transmission 
potential for measles in a totally susceptible population 
and on the proportion susceptible in each age group. Roij 
is the average number of secondary cases in the ith age 
group caused by an infectious individual in the jth age 
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group if all individuals in the ith age group are suscep- 
tible to infection. Values for Roij from previous studies in 
the UK and Canada were used:lO 
If only a proportion xi of the ith age group is susceptible 
to infection, then &j, the number of secondary infections 
in that group caused by an infectious individual in the jth 
age group, is given simply by Rq=Roij xi. The overall R is 
calculated as the leading eigenvalue of the next- 
generation matrix Rij.” 
Ethics approval 
The serosurvey was approved by appropriate institu- 
tional ethics committees and the state-wide Health Con- 
fidentiality and Ethics Committee of the New South 
Wales Health Department. 
RESULTS 
Using serosurvey results when equivocal results were 
grouped with positive results, the values of R calculated 
before and after the MCC were 0.90 and 0.57, respec- 
tively. When equivocal serology results were classed as 
negative, the values of R were 1.25 before, and 0.93 after, 
the MCC. 
Figure 1 shows the notifications of measles before 
and after the MCC, and shows that measles notifications 
declined after the MCC. Figure 2 shows the serosurvey 
results by age before and after the MCC. Immunity 
to measles improved in the target age groups after the 
MCC. Figure 3 shows the predicted R for measles up 
to 2010 in Australia for varying levels of vaccination 
coverage. In the worst case scenario (based on ACIR 
vaccine coverage data and assuming no improvement in 
coverage), 13% of 5-12-year-olds and 19% of 1-5-year- 
olds will be susceptible by 2006. The vaccination levels 
used in the various scenarios are shown in Table 1. Figure 
4 shows the R values for selected DGPs in Australia, and 
shows the projected time when each will exceed the 
epidemic threshold if vaccination coverage remains at 
current levels. There is a wide variation in the level of 
measles control between DGPs. 
DISCUSSION 
The Australian MCC was successful in reducing suscepti- 
bility to measles in the target age groups, as demon- 
strated by the serosurvey results. Modeling shows that 
the MCC was successful in interrupting transmission of 
measles in Australia, as demonstrated by a reduction 
of R below the epidemic threshold. However, if ACIR 
data, which we presented as the worst case scenario, are 
correct, and there is no improvement in coverage, R will 
exceed the epidemic threshold by 2007. In this case, 
another catch-up campaign will be needed in 2005-2006, 
targeting pre-school and school-aged children who have 
not received two doses of MMR. However, studies 
suggest that the ACIR underestimates coverage by 
4-7%,12 and if the ACIR data were adjusted for such 
levels of underreporting, the true coverage for two doses 
would be 73-75%. If this is the case, the epidemic 
threshold will be crossed in 2010. This scenario is still 
significantly worse than our ‘best case’ scenario. 
Our study also showed a large amount of variation 
in coverage levels between DGPs in Australia, with 
coverage of two doses ranging from 40% to 77%. Our 
modeling indicates that some DGPs may already be 
exceeding the epidemic threshold for measles. We have 
not excluded differential underreporting as a factor in 
this apparent variation, and intend to feed back results 
to individual DGPs and ask for their assistance in inter- 
preting the results. 
One reason why coverage with two doses of MMR 
may be low is that the second dose, unlike with all 
previous scheduled vaccines, is not subject to an 
incentive payment for medical practitioners. In 1998, 
incentive payments for medical practitioners were 
introduced for scheduled vaccines at 2,4,6, 12 and 18 
months, but not for the 4-year MMR dose.s 
Parental and provider factors may also play a role 
in low uptake of the second dose of MMR. A UK study 
showed that MMR vaccination, particularly the second 
dose, is not perceived to be important for children’s 
health.‘” A survey of the attitudes of medical practi- 
tioners to MMR vaccination showed that there was 
significant misinformation and confusion regarding the 
need for a second dose, with only 20% of practitioners 
stating that they would unequivocally recommend the 
second dose to a wavering parent.14 
Mathematical modeling has shown that a catch-up 
campaign must be used in conjunction with high levels 
of coverage achieved through a routine two-dose 
schedule, and that a catch-up campaign alone has only 
transient benefits.‘O The success of the Australian MCC 
must be consolidated by improving and maintaining 
Table 1. Vaccine coverage estimates used in case scenarios for 
predicting R in the future 
Vaccine coverage 
Best case Middle Worst case 
scenario (%) scenario (%) scenario (AC/R) (%) 
2 doses 
by 5 years 84 77 70 
1 dose 
by 5 years 12 16 20 
0 doses 
by 5 years 4 7 10 
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Figure 1. Measles notifications, Australia, 1997-2000. 
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Figure 2. Percentage-positive* for measles IgG before and after measles control campaign. 
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Figure 3. Effect on R for measles of varying vaccination coverage. 
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Figure 4. R for selected Australian divisions of general practice. 
high levels of coverage with two doses of MMR. Our 
study indicates that the ideal coverage target is at least 
84%, with two doses at 5 years of age, and less than 
4% of children unvaccinated at school entry. Efforts to 
achieve this target are particularly important in light 
of recent adverse media publicity about MMR vaccine 
and autism,15 and the impact that this may have on 
coverage.16.” 
The limitations of this study include those associated 
with an opportunistic serosurvey. Sera collected for 
diagnostic testing of other diseases may introduce a 
selection bias. However, comparisons between our 
results and those of a prospective serosurvey designed 
specifically to evaluate the MCC in one state of 
Australia,Victoria,‘s show comparable results, indicating 
+ DGP 1 
+ DGP2 
+ DGP3 
s DGP3 
- DGP4 
-=- DGP6 
e DGP7 
that the effects of such bias are minimal. The limitation 
of using ACIR data for the calculation of vaccination 
coverage relates to the degree of underreporting to the 
ACIR, leading to underestimation of coverage. We dealt 
with this by using the ACIR data as our ‘worst case 
scenario’, and using two other scenarios with higher 
levels of coverage. Mathematical modeling has some 
limitations, mainly the applicability of population con- 
tact patterns derived from the UK and Canada to an 
Australian setting. However, childcare and schooling 
patterns (which determine the highest levels of contact) 
are similar in these three countries. 
Despite these limitations, mathematical modeling is 
useful in evaluating disease control, as it can summarize 
serologic profiles by a single parameter, the repro- 
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duction number R, which quantifies the level of herd 
immunity in the population, and allows prediction of 
epidemics9 This provides far more information than 
simple disease notification data or age-serologic profiles 
alone, and allows more rational planning of public health 
programs. Our study demonstrates that, in the absence 
of regular serosurvey data, knowledge of vaccine coverage 
can allow the monitoring of measles control. Australia 
is in a position to do this, with a centralized national 
register of immunization rec0rds.s 
The WHO has set a target for global eradication of 
measles.19 As individual countries and regions approach 
elimination, good surveillance is important, and can be 
enhanced by monitoring R over time.s In this context, 
elimination (or cessation of indigenous transmission 
of disease) can be considered to be achieved if R is 
maintained below 1.5 In Australia, we need to improve 
vaccination coverage with two doses of MMR in order 
to achieve this in the long term. We believe that modeling 
is useful for translating serosurvey and vaccine coverage 
data into predictive tools to assist public health planning 
and policy. 
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